The Herbal Drug, Polysaccharide K, has an Immunological and Synergistic Anticancer Effect with Cetuximab for Gastrointestinal Cancer in Vivo

mshara Unknown

Authors

mshara Unknown

Keywords:

Abstract

Cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, has been widely used for therapy of several kinds of malignant diseases. However, the anticancer effect is incomplete. The purpose of this study was to examine the synergism between the herbal drug, Polysaccharide K, and Cetuximab against gastrointestinal cancer cell lines in vitro and in vivo. Two gastrointestinal cancer cell lines positive for EGFR expression were used for this study. In the in vivo study, mice were xenografted with cancer cell lines subcutaneously. Neither PSK nor Cetuximab suppressed cell proliferation. However, when both drugs were administered, cancer growth was suppressed significantly compared with treatment with Cetuximab alone. This study demonstrated that PSK has the potential to enhance Cetuximab's effect on gastrointestinal cancer.

Downloads

How to Cite

The Herbal Drug, Polysaccharide K, has an Immunological and Synergistic Anticancer Effect with Cetuximab for Gastrointestinal Cancer in Vivo. (2013). Global Journal of Medical Research, 13(17), 2-3. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

H. Lu (2011) TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy. 17(21), 6742-6753. https://doi.org/10.1158/1078-0432.ccr-11-1142

S. Ohwada (2004) Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. 90(6), 1003-. https://doi.org/10.1038/sj.bjc.6602101

K. Ito Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.

S. Ohwada (2003) Adjuvant Therapy With Protein-Bound Polysaccharide K and Tegafur Uracil in Patients With Stage II or III Colorectal Cancer: Randomized, Controlled Trial. 46(8), 1060-1068. https://doi.org/10.1007/s10350-004-7281-y

(2006) CALGB/SWOG C80405: A phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab or both for untreated metastatic adenocarcinoma of the colon or rectum. 4, 452-453.

S. Politano (2008) Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. 7(1), 55-59. https://doi.org/10.3816/ccc.2008.n.008

N. Moosmann, V. Heinemann Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer.

Shelby Terstriep, Axel Grothey (2006) First- and second-line therapy of metastatic colorectal cancer. 6(6), 921-930. https://doi.org/10.1586/14737140.6.6.921

M. Saif (2009) Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. 65(1), 107-112. https://doi.org/10.1007/s00280-009-1009-6

Muhammad Saif, J. Peccerillo, Von Potter (2009) Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. 63(6), 1017-1022. https://doi.org/10.1007/s00280-008-0831-6

Eric Van Cutsem (2006) Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. 11(9), 1010-1017. https://doi.org/10.1634/theoncologist.11-9-1010

M. Hara (2008) Interleukin‐2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor‐overexpressing gastric cancer xenografts through antibody‐dependent cellular cytotoxicity. 99(7), 1471-1478. https://doi.org/10.1111/j.1349-7006.2008.00821.x

A. Rosendahl, C. Sun, D. Wu, R. Andersson Polysaccharide-K (PSK) increases p21(WAF/Cip1) and promotes apoptosis in pancreatic cancer cells.

J. Lin (2011) The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. 104(6), 661-666. https://doi.org/10.1002/jso.21993